BerGenBio AS (BRRGF) has released an update.
BerGenBio AS, a Norwegian biopharmaceutical firm, has reported promising developments in the clinical progress of its leading AXL inhibitor, bemcentinib, and a strong financial position with reduced operating expenses and successful capital raise through warrants exercise. The company is advancing bemcentinib’s Phase 2a study in non-small cell lung cancer, targeting a patient market estimated between $4-5 billion.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
